S'abonner

Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation - 01/08/14

Doi : 10.1016/j.jaci.2013.12.1035 
Md Ashik Ullah, M Pharm a, b, Zhixuan Loh, B Biomed Sci b, Wan Jun Gan, B Biomed Sci b, Vivian Zhang, PhD b, Huan Yang, PhD c, Jian Hua Li, PhD c, Yasuhiko Yamamoto, PhD d, Ann Marie Schmidt, PhD e, Carol L. Armour, PhD a, J. Margaret Hughes, PhD a, f, Simon Phipps, PhD b, , Maria B. Sukkar, PhD a, g,
a Woolcock Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, Australia 
b Laboratory for Respiratory Neuroscience and Mucosal Immunity, School of Biomedical Sciences, University of Queensland, Brisbane, Australia 
c Laboratory of Biomedical Science, Feinstein Institute for Medical Research, New York, NY 
d Department of Biochemistry and Molecular Vascular Biology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan 
e Department of Pathology, Langone Medical Centre, New York University, New York, NY 
f Faculty of Pharmacy, University of Sydney, Sydney, Australia 
g School of Pharmacy, Graduate School of Health, University of Technology, Sydney, Australia 

Corresponding author: Maria B. Sukkar, PhD, School of Pharmacy, Graduate School of Health, The University of Technology, Sydney, Broadway, NSW, 2007, Australia.Simon Phipps, PhD, School of Biomedical Sciences, University of Queensland, St Lucia, QLD, 4072, Australia.

Abstract

Background

The receptor for advanced glycation end products (RAGE) shares common ligands and signaling pathways with TLR4, a key mediator of house dust mite (Dermatophagoides pteronyssinus) (HDM) sensitization. We hypothesized that RAGE and its ligand high-mobility group box-1 (HMGB1) cooperate with TLR4 to mediate HDM sensitization.

Objectives

To determine the requirement for HMGB1 and RAGE, and their relationship with TLR4, in airway sensitization.

Methods

TLR4−/−, RAGE−/−, and RAGE-TLR4−/− mice were intranasally exposed to HDM or cockroach (Blatella germanica) extracts, and features of allergic inflammation were measured during the sensitization or challenge phase. Anti-HMGB1 antibody and the IL-1 receptor antagonist Anakinra were used to inhibit HMGB1 and the IL-1 receptor, respectively.

Results

The magnitude of allergic airway inflammation in response to either HDM or cockroach sensitization and/or challenge was significantly reduced in the absence of RAGE but not further diminished in the absence of both RAGE and TLR4. HDM sensitization induced the release of HMGB1 from the airway epithelium in a biphasic manner, which corresponded to the sequential activation of TLR4 then RAGE. Release of HMGB1 in response to cockroach sensitization also was RAGE dependent. Significantly, HMGB1 release occurred downstream of TLR4-induced IL-1α, and upstream of IL-25 and IL-33 production. Adoptive transfer of HDM-pulsed RAGE+/+dendritic cells to RAGE−/− mice recapitulated the allergic responses after HDM challenge. Immunoneutralization of HMGB1 attenuated HDM-induced allergic airway inflammation.

Conclusion

The HMGB1-RAGE axis mediates allergic airway sensitization and airway inflammation. Activation of this axis in response to different allergens acts to amplify the allergic inflammatory response, which exposes it as an attractive target for therapeutic intervention.

Le texte complet de cet article est disponible en PDF.

Key words : Asthma, allergic sensitization, epithelium, TLR4, RAGE, IL-1α, HMGB1, IL-25, IL-33, TSLP

Abbreviations used : AEC, BALF, CCL, CR, DAMP, DC, HMGB1, HDM, IL-1R, PRR, RAGE, TLR4, WT


Plan


 This work was funded by a Deputy Vice Chancellor Bridging Grant (University of Sydney) and seed funding (University of Technology, Sydney) awarded to M.B.S., and an NHMRC Australia Project Grant (1023756) awarded to S.P.
 Conflicts of interest: J. M. Hughes is employed by the National Health and Medical Research Council (NHMRC) of Australia Grant Review Panel Membership 2013; has received research support from the NHMRC of Australia (Project Grant APP 632830 2010-2012); and has received lecture fees from Learning Solutions, The University of Sydney Early Career Researcher Biomedical Program 2011-2012. The rest of the authors declare that they have no relevant conflicts of interest.


© 2014  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 134 - N° 2

P. 440 - août 2014 Retour au numéro
Article précédent Article précédent
  • Neonatal rhinovirus induces mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid cells
  • Jun Young Hong, J. Kelley Bentley, Yutein Chung, Jing Lei, Jessica M. Steenrod, Qiang Chen, Uma S. Sajjan, Marc B. Hershenson
| Article suivant Article suivant
  • Loss of regulator of G protein signaling 5 promotes airway hyperresponsiveness in the absence of allergic inflammation
  • Nariman A. Balenga, William Jester, Meiqi Jiang, Reynold A. Panettieri, Kirk M. Druey

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.